MIR103B2

Summary

MIR103B2 (microRNA 103b-2, HGNC:35385) is a microRNA gene on chromosome 20p13.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 100302282 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:35385
Approved symbol	MIR103B2
Name	microRNA 103b-2
Location	20p13
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-103-2-as, hsa-mir-103b-2
Ensembl gene	ENSG00000283320
Ensembl biotype	miRNA
Entrez	100302282
RNAcentral	URS000075D426 — ncRNA, 62 nt, 4 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000637051

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000637051 — 1 exons

Exon	Start	End
ENSE00003798546	3917502	3917563

Expression profiles

Bgee: expression breadth broad, 12 present calls, max score 77.04.

Top tissues by expression

12 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	77.04	gold quality
prefrontal cortex	UBERON:0000451	73.90	gold quality
islet of Langerhans	UBERON:0000006	73.46	gold quality
body of pancreas	UBERON:0001150	72.94	gold quality
heart left ventricle	UBERON:0002084	72.37	gold quality
gastrocnemius	UBERON:0001388	72.06	gold quality
transverse colon	UBERON:0001157	68.38	gold quality
tibial nerve	UBERON:0001323	67.07	gold quality
subcutaneous adipose tissue	UBERON:0002190	66.92	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	66.90	gold quality
skin of abdomen	UBERON:0001416	65.47	gold quality
esophagus mucosa	UBERON:0002469	63.07	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 4)

• MiR-103 significantly promotes cancer cell proliferation, invasion and metastasis, and, thus, could be an important mediator in the pathogenesis of colorectal cancer Through regulation of colorectal cancer cell DICER and PTEN expression. (PMID:24828205)
• miR-103 is involved in insulin resistance and NAFLD, and may be a molecular link between insulin resistance and NAFLD (PMID:25593466)
• Study results demonstrated that serum miR-103 was overexpressed in colorectal cancer (CRC) subjects, could differentiate CRC cases from controls with relatively high accuracy, and significantly correlated with worse clinical factors, as well as poorer recurrence-free survival or overall survival. Taken together, serum miR-103 might be a promising biomarker for diagnosis and prognosis of CRC. (PMID:30058684)
• Clinical data indicates that a high expression of miR103 is associated with the progression of hepatocellular carcinoma (HCC). Further results suggest that miR103 promotes HCC metastasis and EMT by directly inhibiting LATS2. (PMID:30272278)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.